Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alternative tobacco bill in Senate

This article was originally published in The Tan Sheet

Executive Summary

Sen. Richard Burr, R-N.C., introduces the Federal Tobacco Bill, S. 579, to establish an agency to regulate the manufacture, marketing and use of tobacco products under the Department of Health and Human Services. The legislation is similar to the Youth Prevention and Tobacco Harm Reduction Act, H.R. 1261, introduced March 3 by Rep. Steve Buyer, R-Ind. (1"The Tan Sheet" March 9, 2009, p. 3). During an Energy and Commerce Committee markup March 4, Buyer touted his tobacco bill as an alternative to Chairman Henry Waxman's, D-Calif., Family Smoking Prevention and Tobacco Control Act, H.R. 1256, which would make tobacco an FDA-regulated product. Waxman's bill passed the committee and will move to a floor vote

You may also be interested in...

Tobacco Oversight Looks More Likely, But Is It Bad For FDA’s Health?

The likelihood of Congress handing FDA responsibility for regulating tobacco has ignited debate over whether the new purview would distract an already struggling agency from its mission

EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty

Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.

Emerging Markets Help Fresenius Kabi Offset US Pressures

Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts